Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.
Also called NCT01279590
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 282 participants
- Sponsor
- Furiex Pharmaceuticals, Inc
- Registry
-
NCT01279590
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01279590. Randomized; quadruple masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2011-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
- Condition
- Myalgia
- Condition
- Hypercholesterolemia
- Condition
- Hyperlipidemia
- Intervention (Drug)
- PPD10558
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Furiex Pharmaceuticals, Inc
Record details
- Record id
cardio:ct-nct01279590- Content hash
7ad980993cd2208e6049798891ca8d4a9a66a74be3e0fccfd0658b867a3e24e6